<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A clinical study of the adverse effects induced by the <z:chebi fb="32" ids="24621">endocrine</z:chebi> therapy with a high dose of <z:chebi fb="0" ids="50114">estrogen</z:chebi> in 45 patients with stage C or D prostatic <z:mp ids='MP_0002038'>carcinoma</z:mp> is conducted </plain></SENT>
<SENT sid="1" pm="."><plain>Transient decreases of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> and serum protein values were observed after administration of <z:chebi fb="0" ids="50114">estrogen</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The levels of glutamine-oxaloacetic and glutamic-pyruvic transaminase showed a transient increase </plain></SENT>
<SENT sid="3" pm="."><plain>The value of serum total cholesterol and electrolytes showed no changes </plain></SENT>
<SENT sid="4" pm="."><plain>Serial evaluations of electrocardiograms have played a minor role in the observation of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Up to date we have not experienced cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> in our cases during the <z:chebi fb="32" ids="24621">endocrine</z:chebi> therapy </plain></SENT>
</text></document>